Bristol-Myers: Baraclude Data In Line With Prior Findings

[Guest guest]

Bristol-Myers: Baraclude Data In Line With Prior Findings

March 24, 2008: 08:48 AM EST

DOW JONES NEWSWIRES

Bristol-Myers Squibb Co. (BMY) reported new Baraclude data demonstrated a

continued low incidence of resistance in nucleoside-naive chronic hepatitis B

patients through five years of treatment.

In the patients analyzed, no additional patients developed resistance in the

fifth year, the biopharmaceutical and health-care products company said Monday.

Through five years of treatment, the cumulative probability of developing

mutations in the virus that confer resistance to Baraclude was 1.2%.

In lamivudine-refractory patients who received Baraclude after treatment with

lamivudine failed, the cumulative probability of genotypic Baraclude resistance

was 51% through the fifth year. This finding is consistent with prior

observations, the company said.

- Park; 201-938-5400; AskNewswires@...

(END) Dow Newswires

03-24-08 0848ET

Copyright © 2008 Dow & Company, Inc.

http://money.cnn.com/news/newsfeeds/articles/djf500/200803240848DOWJONESDJONLINE\

000118_FORTUNE5.htm

_________________________________________________________________

In a rush? Get real-time answers with Windows Live Messenger.

http://www.windowslive.com/messenger/overview.html?ocid=TXT_TAGLM_WL_Refresh_rea\

ltime_042008